NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for DaVita investors under the federal securities laws.
To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
First Western Ship Transits Strait of Hormuz Since Iran War Began
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 



